Global Gabapentin Market Statistics: USD 3.4 Billion Value by 2032
Summary:
- The global gabapentin market size reached USD 2.2 Billion in 2023.
- The market is expected to reach USD 3.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.13% during 2024-2032.
- North America leads the market, accounting for the largest gabapentin market share.
- Capsule accounts for the majority of the market share in the dosage form segment, which can be attributed to its ability to dissolve and absorb quickly in the gastrointestinal system.
- Generic holds the largest share in the gabapentin industry.
- Epilepsy remains a dominant segment in the market due to the increasing need for managing seizures.
- Hospital pharmacy represents the leading distribution channel segment.
- The rising prevalence of neuropathic pain and epilepsy is a primary driver of the gabapentin market.
- The off-label expansion and increasing awareness and accessibility are reshaping the gabapentin market.
Industry Trends and Drivers:
- Growing Prevalence of Neuropathic Pain and Epilepsy:
The increasing prevalence of neuropathic pain and epilepsy among the masses around the world is contributing to the market growth. Neuropathic pain is often linked with diabetes, cancer, and other chronic conditions, which are becoming more common as the global population ages. Gabapentin is proven effective in treating this type of pain, making it a go-to option for healthcare providers. Similarly, epilepsy continues to affect millions of people globally, with a growing number of new diagnoses each year. Gabapentin, approved as an anticonvulsant, plays a vital role in managing epilepsy symptoms. These conditions are particularly widespread in regions with aging populations, such as North America and Europe, where chronic disease management is a priority.
- Off-Label Expansion:
Gabapentin's off-label use has significantly impelled the market growth. While originally approved for the treatment of epilepsy and neuropathic pain. Gabapentin is frequently prescribed for conditions, such as anxiety, migraines, and restless leg syndrome. Its broad applicability in managing various types of pain and mood disorders makes it a versatile medication. Physicians are recommending it on account of its favorable side-effect profile as compared to other stronger medications like opioids, which are associated with addiction risks. In regions where pain management is a high priority, such as North America and Europe, off-label prescriptions of gabapentin are quite common. This off-label expansion enhances its reach beyond its approved indications, positioning gabapentin as a multi-purpose drug in both developed and developing markets.
- Rising Awareness and Accessibility:
The increasing awareness among individuals about conditions like neuropathic pain and epilepsy, combined with improving access to healthcare services, is impelling the market growth. Public health campaigns and greater diagnostic capabilities are leading to earlier detection and treatment of these conditions, making gabapentin a commonly prescribed medication. Moreover, the expansion of healthcare infrastructure in emerging economies is improving access to medications like gabapentin. As more patients are diagnosed with neuropathic conditions or epilepsy, their demand for effective treatment grows, contributing to market expansion. In addition, the rising availability of generic versions of gabapentin makes it a cost-effective option for both healthcare providers and patients, especially in regions where healthcare resources are limited.
Request for a sample copy of this report: https://www.imarcgroup.com/gabapentin-market/requestsample
Gabapentin Market Report Segmentation:
Breakup By Dosage Form:
- Tablet
- Capsule
- Oral Solutions
Capsule account for the majority of shares, which can be attributed to its ability to dissolve and absorb quickly in the gastrointestinal system.
Breakup By Type:
- Generic
- Branded
Generic dominates the market on account of the rising focus on healthcare affordability.
Breakup By Application:
- Epilepsy
- Neuropathic Pain
- Restless Legs Syndrome
- Others
Epilepsy represents the majority of shares due to the increasing need for managing seizures.
Breakup By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Hospital pharmacy hold the majority of shares as they provide immediate availability of drugs for acute conditions that require prompt medication.
Breakup By Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America enjoys the leading position owing to a large market for gabapentin driven by the presence of the highly developed healthcare system.
Top Gabapentin Market Leaders:
The gabapentin market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:
- Alkem Laboratories Limited
- Amneal Pharmaceuticals LLC
- Apotex Inc.
- Aurobindo Pharma Limited
- Azurity Pharmaceuticals, Inc.
- Cipla Inc.
- Glenmark Pharmaceuticals Limited
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Zydus Pharmaceuticals (USA) Inc. (Zydus LifeScience).
Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1–631–791–1145
Comments
0 comment